InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc.

LENZ Clue Score49
United States Fiscal year ends December CIK 0001815776
$3.65 +3.26% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.65 −74.63% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Jun 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−13.5Net income−68.4Fiscal year 2021Operating income−60.4Net income−70.8EPS, diluted−2.45Fiscal year 2022Operating income−105.6Net income−101.1EPS, diluted−1.84Fiscal year 2023Operating income−72.4Net income−70.0EPS, diluted−35.71Fiscal year 2024Revenue0.0Operating income−58.6Net income−49.8EPS, diluted−2.34Fiscal year 2025Revenue19.1Operating income−91.1Net income−82.1EPS, diluted−2.85
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 0.0 19.1
Growth
Operating income −13.5 −60.4 −105.6 −72.4 −58.6 −91.1
Net income −68.4 −70.8 −101.1 −70.0 −49.8 −82.1
Growth
EPS, diluted n/a −2.45 −1.84 −35.71 −2.34 −2.85

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025Operating margin−477.5%Net margin−430.3%Free cash flow margin−366.7%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a −477.5%
Net margin n/a n/a n/a n/a n/a −430.3%
Free cash flow margin n/a n/a n/a n/a n/a −366.7%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−8.7Capital expenditure−1.5Free cash flow−10.3Fiscal year 2021Operating cash flow−52.9Capital expenditure−5.7Free cash flow−58.6Fiscal year 2022Operating cash flow−88.0Capital expenditure−6.6Free cash flow−94.6Fiscal year 2023Operating cash flow−60.4Capital expenditure−0.0Free cash flow−60.4Fiscal year 2024Operating cash flow−59.4Capital expenditure−0.5Free cash flow−59.9Fiscal year 2025Operating cash flow−69.2Capital expenditure−0.8Free cash flow−70.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −8.7 −52.9 −88.0 −60.4 −59.4 −69.2
Capital expenditure −1.5 −5.7 −6.6 −0.0 −0.5 −0.8
Free cash flow −10.3 −58.6 −94.6 −60.4 −59.9 −70.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash19.8Shareholders’ equity−65.4Fiscal year 2021Cash377.0Shareholders’ equity384.1Fiscal year 2022Cash47.7Shareholders’ equity−24.2Fiscal year 2023Cash35.1Shareholders’ equity−92.7Fiscal year 2024Cash20.2Shareholders’ equity204.1Fiscal year 2025Cash25.2Shareholders’ equity284.3
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 19.8 377.0 47.7 35.1 20.2 25.2
Shareholders’ equity −65.4 384.1 −24.2 −92.7 204.1 284.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
n/a n/a n/a n/a n/a −477.5%
n/a n/a n/a n/a n/a −427.6%
n/a n/a n/a n/a n/a −430.3%
n/a n/a n/a n/a n/a −366.7%
Spending
n/a n/a n/a n/a n/a 97.8%
n/a n/a n/a n/a n/a 477.5%
n/a n/a n/a n/a n/a 4.3%
Returns
n/a −18.4% n/a n/a −24.4% −28.9%
−303.0% −17.6% −31.4% −99.4% −23.1% −26.8%
Balance and payout
143.4% 4.5% 8.0% 28.0% 5.2% 7.0%